Predicting changes in cardiac myocyte contractility during early drug discovery with in vitro assays.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Toxicology and Applied Pharmacology

• Publication date

  2014-09-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.taap.2014.06.005PMID 24952337
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmaceutical R&D Performance by Firm Size: Approval Success Rates and Economic Returns

  2014cited by this paper
• Development of a high-throughput electrophysiological assay for the human ether-à-go-go related potassium channel hERG.

  2013cited by this paper
• Use of Escin as a Perforating Agent on the IonWorks Quattro Automated Electrophysiology Platform

  2013cited by this paper
• Agreed statistics: measurement method comparison.

  2012cited by this paper
• Validation of an in vitro contractility assay using canine ventricular myocytes.

  2012cited by this paper
• Assessment of left ventricular dP/dtmax in telemetry studies: Essential or excessive?

  2012cited by this paper
• Reducing safety-related drug attrition: the use of in vitro pharmacological profiling

  2012cited by this paper
• The ‘overly‐sensitive’ heart: sodium channel block and QRS interval prolongation

  2011cited by this paper
• On the relationship between block of the cardiac Na+ channel and drug‐induced prolongation of the QRS complex

  2011cited by this paper
• How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines?

  2011cited by this paper
• Cardiac Ion Channel Safety Profiling on the IonWorks Quattro Automated Patch Clamp System

  2010cited by this paper
• CaV1.2 channelopathies: from arrhythmias to autism, bipolar disorder, and immunodeficiency

  2010cited by this paper
• Optimization of Ca(v)1.2 screening with an automated planar patch clamp platform.

  2009cited by this paper
• Validation of a voltage-sensitive dye (di-4-ANEPPS)-based method for assessing drug-induced delayed repolarisation in beagle dog left ventricular midmyocardial myocytes.

  2009cited by this paper
• A framework to assess the translation of safety pharmacology data to humans.

  2009cited by this paper
• Calcium channel antagonists: clinical uses--past, present and future.

  2007cited by this paper
• Vascular-specific increase in exon 1B-encoded CAV1.2 channels in spontaneously hypertensive rats.

  2006cited by this paper
• Exploiting high-throughput ion channel screening technologies in integrated drug discovery.

  2006cited by this paper
• Optimisation and validation of a medium-throughput electrophysiology-based hERG assay using IonWorks HT.

  2006cited by this paper
• Can the pharmaceutical industry reduce attrition rates?

  2004cited by this paper
• International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on Terms and Symbols in Quantitative Pharmacology

  2003cited by this paper
• Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development.

  2003cited by this paper
• Molecular Pharmacology of High Voltage-Activated Calcium Channels

  2003cited by this paper
• Predicting ADME properties and side effects: the BioPrint approach.

  2003cited by this paper
• The ECVAM International Validation Study on In Vitro Embryotoxicity Tests: Results of the Definitive Phase and Evaluation of Prediction Models

  2002cited by this paper
• Cardiac excitation–contraction coupling

  2002cited by this paper
• Nomenclature of voltage-gated sodium channels.

  2000cited by this paper
• Nomenclature of voltage-gated calcium channels.

  2000cited by this paper
• Safety of calcium-channel blockers.

  1998cited by this paper
• Molecular determinants of drug binding and action on L-type calcium channels.

  1997cited by this paper
• The effect of calcium ion channel blockers on sperm fertilization potential.

  1994cited by this paper
• Pharmacology of positive inotropic phosphodiesterase III inhibitors.

  1989cited by this paper
• Side Effects of Calcium Channel Blockers

  1988cited by this paper
• (-)-[3H] desmethoxyverapamil labels multiple calcium channel modulator receptors in brain and skeletal muscle membranes: differentiation by temperature and dihydropyridines.

  1986cited by this paper
• [3H]diltiazem binding to calcium channel antagonists recognition sites in rat cerebral cortex.

  1985cited by this paper
• [3H]nitrendipine-labeled calcium channels discriminate inorganic calcium agonists and antagonists.

  1982cited by this paper
• The Effect of Concurrent Oral Administration of Propranolol and Disopyramide on Cardiac Function in Healthy Men

  1980cited by this paper
• Describing the validity of carcinogen screening tests.

  1979cited by this paper

• Anticancer drugs and cardiotoxicity: the role of cardiomyocyte and non-cardiomyocyte cells

  2024cites this paper
• Endothelial cell dysfunction in cardiac disease: driver or consequence?

  2023cites this paper
• Cardiovascular microphysiological systems (CVMPS) for safety studies - a pharma perspective.

  2021cites this paper
• Cardiovascular Safety Pharmacology Issue Resolution

  2019cites this paper
• Predicting QRS and PR interval prolongations in humans using nonclinical data

  2017influential citation
• From the Cover: High-Throughput Imaging of Cardiac Microtissues for the Assessment of Cardiac Contraction during Drug Discovery

  2017cites this paper
• Contribution of Automated Technologies to Ion Channel Drug Discovery.

  2016cites this paper
• PKPD modelling of PR and QRS intervals in conscious dogs using standard safety pharmacology data.

  2016cites this paper
• Optimization of a High-Throughput Assay for Calcium Channel Modulators on IonWorks Barracuda

  2016cites this paper
• Structural and functional screening in human induced-pluripotent stem cell-derived cardiomyocytes accurately identifies cardiotoxicity of multiple drug types.

  2015cites this paper
• Ion channels as medicinal targets of biological toxins: the impact of automated patch-clamp electrophysiology.

  2015cites this paper
• Cardiovascular safety risk assessment for new candidate drugs from functional and pathological data: Conference report.

  2015cites this paper